Explanipedia

Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial Open

Martin S. Maron, Juan R. Gimeno, Josef Veselka, Roberto Barriales‐Villa, Brian Claggett , et al. · 2025

Background and Aims Patients with obstructive hypertrophic cardiomyopathy (oHCM) treated with aficamten in SEQUOIA-HCM (NCT05186818) demonstrated marked improvement in symptoms and functional capacity. This analysis explores whether oHCM a…

Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy Open

Martin S. Maron, Ahmad Masri, Michael E. Nassif, Roberto Barriales‐Villa, Theodore P. Abraham , et al. · 2024

Aficamten and Cardiopulmonary Exercise Test Performance Open

Matthew M.Y. Lee, Ahmad Masri, Michael E. Nassif, Roberto Barriales‐Villa, Theodore P. Abraham , et al. · 2024

Importance Impaired exercise capacity is a cardinal manifestation of obstructive hypertrophic cardiomyopathy (HCM). The Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Obstructi…

Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy Open

Charles F Sherrod, Sara Saberi, Michael E. Nassif, Brian Claggett, Caroline Coats , et al. · 2024

In patients with symptomatic oHCM, treatment with aficamten resulted in markedly improved health status, including significant improvement in chest pain-related health status, than placebo. (Phase 3 Trial to Evaluate the Efficacy and Safet…

It has been 30 years since the first alcohol septal ablation for hypertrophic obstructive cardiomyopathy was performed Open

Josef Veselka · 2024

No abstract available.

Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM Open

Caroline Coats, Ahmad Masri, Michael E. Nassif, Roberto Barriales‐Villa, Michael Arad , et al. · 2024

Background Aficamten, a novel cardiac myosin inhibitor, reversibly reduces cardiac hypercontractility in obstructive hypertrophic cardiomyopathy. We present a prespecified analysis of the pharmacokinetics, pharmacodynamics, and safety of a…

Relationship Between Genotype Status and Clinical Outcome in Hypertrophic Cardiomyopathy Open

Jiří Bonaventura, Ethan J. Rowin, Raymond H. Chan, Michael T. Chin, Veronika Puchnerová , et al. · 2024

Background The genetic basis of hypertrophic cardiomyopathy (HCM) is complex, and the relationship between genotype status and clinical outcome is incompletely resolved. Methods and Results We assessed a large international HCM cohort to d…

Table of Contents Open

Athanasios Bakalakos, Emanuele Monda, Perry Elliott, Saif Dababneh, Homa Hamledari , et al. · 2024

Hypertrophic Cardiomyopathy: Evolution to the Present, Ongoing Challenges, and Opportunities Open

William J. McKenna, Andrew Crean, Steven C. Greenway, Rafik Tadros, Josef Veselka , et al. · 2024

Effect of metoprolol in hypertrophic obstructive cardiomyopathy patients after alcohol septal ablation Open

Hana Hnátová, Klára Fulínová, Barbora Řiháková, Jiří Bonaventura, Josef Veselka · 2023

In HOCM patients after successful ASA, metoprolol treatment did not improve exercise capacity, hemodynamic and laboratory parameters, or quality of life.

Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy Open

Caroline Coats, Martin S. Maron, Theodore P. Abraham, Iacopo Olivotto, Matthew M.Y. Lee , et al. · 2023

Mortality in hypertrophic cardiomyopathy is unrelated to genotype Open

Jiří Bonaventura, Ethan J. Rowin, Michael T. Chin, Veronika Puchnerová, E Polakova , et al. · 2023

Background Hypertrophic cardiomyopathy (HCM) patients with a pathogenic variant are presumed to have worse prognosis than patients without a pathogenic mutation. However, the genetic basis of hypertrophic cardiomyopathy (HCM) is complex, a…

Announcement: Call for Papers: Focus Issue on Hypertrophic Cardiomyopathy in Rapid Evolution Open

Andrew Crean, Steven C. Greenway, William J. McKenna, Rafik Tadros, Josef Veselka , et al. · 2023

2023 ESC Guidelines for the management of cardiomyopathies Open

Elena Arbelo, Alexandros Protonotarios, Juan R. Gimeno, Eloisa Arbustini, Roberto Barriales‐Villa , et al. · 2023

Guidelines evaluate and summarize available evidence with the aim of assisting health professionals in proposing the best diagnostic or therapeutic approach for an individual patient with a given condition. Guidelines are intended for use …

Announcement: Call for Papers: Focus Issue on Hypertrophic Cardiomyopathy in Rapid Evolution Open

Andrew Crean, Steven C. Greenway, William J. McKenna, Rafik Tadros, Josef Veselka , et al. · 2023

Eicosanoids in human heart failure: pilot study of plasma epoxyeicosatrienoic and dihydroxyeicosatrienoic acid levels Open

Petr Kala, Tomáš Hnát, Karolína Pádrová, Karel Kotaška, Josef Veselka · 2023

Introduction The role of eicosanoids, metabolites of arachidonic acid with cardio-renal activity, remains unclear in human heart failure (HF). Material and methods We enrolled 50 patients with HF to measure plasma 14,15-EET and 14,15-DHET …

Endothelin type A receptor blockade attenuates aorto-caval fistula-induced heart failure in rats with angiotensin II-dependent hypertension Open

Petr Kala, Olga Gawryś, Matúš Miklovič, Zdeňka Vaňourková, Petra Skaroupkov , et al. · 2023

Objective: Evaluation of the effect of endothelin type A (ETA) receptor blockade on the course of volume-overload heart failure in rats with angiotensin II-dependent hypertension. Methods: Ren-2 renin transgenic rats (TGR) were used as a m…

Do female patients with hypertrophic cardiomyopathy have a worse prognosis than male patients? Open

Jiří Bonaventura, Veronika Vejtasova, E Polakova, Barbora Řiháková, Josef Veselka · 2022

Aim Sex affects the prognosis of many cardiovascular diseases. This study aimed to assess the predicted sudden cardiac death (SCD) risk and evaluate the actual survival between male and female patients with hypertrophic cardiomyopathy (HCM…

Mid-term outcomes of patients with Lotus and Evolut transcatheter valves Open

Petr Hájek, Eva Polaková, Radka Adlová, Martin Horváth, Eva Hansvenclová , et al. · 2022

The results of our study suggest that higher cardiovascular mortality rates during mid-term follow-up were associated with Lotus compared with Evolut valves. Higher AVGm in the Lotus valves suggests the possibility of accelerated prosthesi…

Prediction of Sudden Cardiac Arrest after Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy (ASA-SCARRE Risk Score) Open

Josef Veselka, Max Liebregts, Robert Cooper, Lothar Faber, Morten K. Jensen , et al. · 2022

The impact of education as a marker of socio-economic status on survival of patients after transcatheter aortic valve implantation Open

Barbora Chabová, Petr Hájek, Radka Adlová, Eva Hansvenclová, Monika Pecková , et al. · 2022

Patients with an LLE required TAVI at a younger age, had more comorbidities and had a more risky profile. Level of education did not influence periprocedural and mid-term outcomes.

Genetic Testing in Patients with Hypertrophic Cardiomyopathy Open

Jiří Bonaventura, Eva Polaková, Veronika Vejtasová, Josef Veselka · 2021

Hypertrophic cardiomyopathy (HCM) is a common inherited heart disease with an estimated prevalence of up to 1 in 200 individuals. In the majority of cases, HCM is considered a Mendelian disease, with mainly autosomal dominant inheritance. …

(Atypical manifestation of Takotsubo syndrome during COPD exacerbation) Open

Michael Jenšovský, Kateřina Pelechová, Josef Veselka · 2021

Takotsubo syndrom (TTS) je onemocnění projevující se jako akutní reverzibilní dysfunkce převážně levé komory. Nejčastěji postihuje postmenopauzální ženy s anamnézou neurologických či psychiatrických onemocnění a psychickým nebo fyzickým st…

Kidney Response to Chemotherapy-Induced Heart Failure: mRNA Analysis in Normotensive and Ren-2 Transgenic Hypertensive Rats Open

Šárka Jíchová, Olga Gawryś, Elżbieta Kompanowska‐Jezierska, Janusz Sadowski, Vojtěch Melenovský , et al. · 2021

The aim of the present study was to perform kidney messenger ribonucleic acid (mRNA) analysis in normotensive, Hannover Sprague–Dawley (HanSD) rats and hypertensive, Ren-2 renin transgenic rats (TGR) after doxorubicin-induced heart failure…

Sex-Related Differences in Outcomes of Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy Open

Josef Veselka, Lothar Faber, Max Liebregts, Robert Cooper, Maksim Kashtanov , et al. · 2021

Alcohol dose in septal ablation for hypertrophic obstructive cardiomyopathy Open

Josef Veselka, Lothar Faber, Max Liebregts, Robert Cooper, Jaroslav Januška , et al. · 2021

TAVI-in-TAVI in a patient after alcohol septal ablation Open

Eva Polaková, Radka Adlová, Petr Hájek, Josef Veselka · 2021

Cardiovascular medicine at its beginning was dominated by surgical treatment options. The trend of the last decades is heading towards catheterization procedures. Alcohol septal ablation (ASA) was published by Sigwart in 1995 [1] whereas t…

Deleterious Effects of Hyperactivity of the Renin-Angiotensin System and Hypertension on the Course of Chemotherapy-Induced Heart Failure after Doxorubicin Administration: A Study in Ren-2 Transgenic Rat Open

Petr Kala, Hana Bartušková, Jan Piťha, Zdeňka Vaňourková, Soňa Kikerlová , et al. · 2020

Doxorubicin’s (DOX) cardiotoxicity contributes to the development of chemotherapy-induced heart failure (HF) and new treatment strategies are in high demand. The aim of the present study was to characterize a DOX-induced model of HF in Ren…

(Complex approach towards patients with hypertrophic cardiomyopathy and indications to genetic testing) Open

Jiří Bonaventura, Alice Krebsová, Veronika Zoubková, Pavel Votýpka, Petra Peldová , et al. · 2020

Hypertrofická kardiomyopatie (HKMP) je s předpokládanou prevalencí 1/500 až 1/200 obyvatel jedním z nejčastějších geneticky podmíněných srdečních onemocnění. Pro HKMP je charakteristická výrazná fenotypová i genotypová heterogenita. Pacien…

Ten Tips and Tricks for Performing Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy Open

Josef Veselka · 2020

Alcohol septal ablation (ASA) is an effective interventional therapeutic strategy to reduce or eliminate left ventricular outflow tract obstruction in patients with hypertrophic obstructive cardiomyopathy (HOCM). Although ASA was introduce…

Josef Veselka YOU? Author Swipe